Patients increasingly opt for bioprosthetic valves to avoid lifelong anticoagulation, however these are limited by durability and need for reintervention. The Edwards Lifesciences INSPIRIS RESILIA valve is a next generation valve designed to have improved anti-calcification properties for sustained haemodynamic performance and to allow for future transcatheter valve-in-valve intervention. We present our clinical outcomes with the INSPIRIS bioprosthesis in comparison to other bioprosthetic valves for aortic valve replacement. Retrospective review of all patients undergoing aortic valve replacement at Flinders Medical Centre from January 2018 to December 2023. The primary outcomes were 30-day mortality and clinical end points, comparing the INSPIRIS bioprosthesis to all other types of bioprosthetic aortic valve. 437 patients underwent aortic valve replacement, of which 257 (59%) received the INSPIRIS bioprosthesis. Aortic stenosis was the indication for surgery in majority of patients. Use of the INSPIRIS bioprosthesis increased from 4% to 94% during the six-year period. The INSPIRIS group had a mean age 62 years, with 52% of INSPIRIS patients aged <65 years compared with 27% of “other” patients; 29% of the INSPIRIS group was female, and the most common valve size was 23 mm. Patients in the INSPIRIS group had lower rates of post operative stroke (1.5% vs. 4.4%), arrhythmia (44% vs. 49%), and permanent pacemaker implantation (2.7% vs. 6.6%). Equivalent rates of acute kidney injury and myocardial infarction were seen between groups. All-cause mortality at 30 days was 0.7% for the INSPIRIS bioprosthesis compared to 3.8% for all other bioprosthetic valves. The INSPIRIS bioprosthesis is becoming a favoured valve choice in younger patients. Our mid-term experience with the INSPIRIS bioprosthesis demonstrates comparative or better outcomes to other bioprosthetic valves in patients undergoing aortic valve replacement. Long term follow-up and correlation with echocardiographic data is warranted.